Catheter Ablation for Ventricular Tachycardia After MI: A Reconstructed Individual Patient Data Meta-analysis of Randomised Controlled Trials

• Published in: Arrhythmia & electrophysiology review 2023-01, Vol.12, p.e26
• Main Authors: Reddy, Rohin K, Howard, James P, Ahmad, Yousif, Shun-Shin, Matthew J, Simader, Florentina A, Miyazawa, Alejandra A, Saleh, Keenan, Naraen, Akriti, Samways, Jack W, Katritsis, George, Mohal, Jagdeep S, Kaza, Nandita, Porter, Bradley, Keene, Daniel, Linton, Nicholas Wf, Francis, Darrel P, Whinnett, Zachary I, Luther, Vishal, Kanagaratnam, Prapa, Arnold, Ahran D
• Format: Article
• Language: English
• Subjects: Ablation (Surgery); Analysis; Cardiac patients; Care and treatment; Defibrillators; Electrophysiology and Ablation; Health aspects; Mortality; United Kingdom; Ventricular tachycardia
• ISSN: 2050-3369; 2050-3377
• DOI: 10.15420/aer.2023.07

The prognostic impact of ventricular tachycardia (VT) catheter ablation is an important outstanding research question. We undertook a reconstructed individual patient data meta-analysis of randomised controlled trials comparing ablation to medical therapy in patients developing VT after MI. We systematically identified all trials comparing catheter ablation to medical therapy in patients with VT and prior MI. The prespecified primary endpoint was reconstructed individual patient assessment of all-cause mortality. Prespecified secondary endpoints included trial-level assessment of all-cause mortality, VT recurrence or defibrillator shocks and all-cause hospitalisations. Prespecified subgroup analysis was performed for ablation approaches involving only substrate modification without VT activation mapping. Sensitivity analyses were performed depending on the proportion of patients with prior MI included. Eight trials, recruiting a total of 874 patients, were included. Of these 874 patients, 430 were randomised to catheter ablation and 444 were randomised to medical therapy. Catheter ablation reduced all-cause mortality compared with medical therapy when synthesising individual patient data (HR 0.63; 95% CI [0.41-0.96]; p=0.03), but not in trial-level analysis (RR 0.91; 95% CI [0.67-1.23]; p=0.53; I =0%). Catheter ablation significantly reduced VT recurrence, defibrillator shocks and hospitalisations compared with medical therapy. Sensitivity analyses were consistent with the primary analyses. In patients with postinfarct VT, catheter ablation reduces mortality.